INTRODUCTION
Psoriasis is a common chronic, autoimmune, inflammatory disease with a global prevalence of 3%. Recently, psoriasis has been associated not only with arthritis but also with disturbances in the lipid and glucose homeostasis. Patients with psoriasis have an increased risk for cardiovascular incidents and neoplasms. In accordance with these data, psoriasis is accepted as a systemic disease with a typical involvement of the skin and joints (1-3). The concept of the anti-inflammatory and immune-regulating function of vitamin D was confirmed by multiple current studies. Deficiency and insufficiency of vitamin D were found in many immune-mediated and neoplastic diseases. So, the role of vitamin D in the pathogenesis of psoriasis, as well as in rheumatoid arthritis, multiple sclerosis, systemic lupus, and inflammatory bowel diseases can be speculated (4) (5) (6) . The assessment of the blood level of 25-hydroxyvi-Stoyan Pavlov, Irina Ivanova, Daniela Gerova tamin D, 25(OH)D, which is a major circulating metabolite of vitamin D is an accepted test for a vitamin D status (7). Our study aimed: to investigate the vitamin D status in patients with Psoriasis vulgaris, consecutively admitted in the Clinic of Dermatology and Venereology -Varna for diagnostics or disease exacerbation; to register the actual severity of psoriasis (PASI) and the type of the disease (early or late, according to age at onset) and to test the relationship between these disease characteristics and the degree of vitamin D insufficiency.
MATERIALS AND METHODS
92 patients, referred for diagnosis and treatment of psoriasis for a 2-year period from January, 2013 to December, 2014 were included in this retrospective study. Psoriasis vulgaris was established based on clinical manifestation and was verified by skin biopsy and consistent morphology. All patients gave written informed consent for the diagnostic procedures. The type of psoriasis was assessed as an early type 1 (onset of the disease at an age below 40 years) and a late type 2 (when psoriasis was diagnosed at age >40) (8) . Concomitant intake of dietary vitamin D supplements, presence of chronic kidney disease, advanced liver disease and malabsorption excluded patients from the study.
At hospital admission we also assessed disease exacerbation according to Psoriasis Area and Severity Index (PASI). PASI objectively classified the actual severity of psoriasis. The index combines the area of affected skin (head -10%; upper extremities -20%; lower extremities 40%; trunk -30% of whole body surface) and the grade of erythema, desquamation and infiltration or induration (scored for each criteria from 0 to 4). Regarding PASI, the psoriasis was categorized as mild (index ≤10), moderate (>10, ≤30) and severe (30 to 72), respectively.
The following data were collected: age at diagnosis and at admission; gender; body mass index (BMI) and waist circumference; C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), serum level of glucose, lipids, uric acid and creatinine. Overweight and obesity were defined according to WHO definitions as BMI≥25 and BMI≥30, respectively.
Serum levels of 25(OH)D were calculated by an immunofluorescent test (ADVIA Centaur Vitamin D Total, Siemens) with assay range of 3.7 to 150ng/ ml (9.3-375 nmol/l). The vitamin D status was classified as deficiency (25(OH)D concentration <10ng/ ml / 25 nmol/l), insufficiency (10-30 ng/ml / 25 -75 nmol/l), sufficiency (>30ng/ml / 75nmol/l) and toxicity (>100ng/ml / 250nmol/l). Serum 25(OH)D levels can be reported in ng/ml (common units) or nmol/l (SI units) with a conversion formula 1 ng/ ml=2.5nmol/l (9,10).
The continuous variables were expressed as a mean value with a standard deviation. The differences between the variables were analyzed with the Mann-Whitney test and the Kruskal-Wallis test (in analyses of more than 2 independent variables). The relations between 25(OH)D and disease characteristics were assessed using the Spearman correlation coefficients. The software used for the analysis was GraphPad Prism, a trial 5.0 version.
RESULTS
The study included 50 male (age 56.69±13.62 years) and 42 female (age 54.12±12.11 years) individuals. Prevalence of overweight and obesity was 56% and 29%; measured waist circumference was 98.28±24.45 cm. Psoriatic patients had increased fasting glucose and diabetes 16.3% and 15.2%, respectively. Total blood cholesterol >5.2 mmol/l was observed in 44% of the study group, but most of them had a borderline elevation and only 9 patients (10%) presented with high cholesterol (>6.2mmol/l). Similarly, triglycerides above 1.7 mmol/l and 2.2 mmol/l were assessed in 25% and 16.3% of the patients, respectively. Only 2 patients had both high cholesterol and high triglycerides. 57.6% of our cases had type 1 psoriasis. The disease was graded as moderate or severe with PASI 32.75±12.07 and the mean value of calculated PASI was found at the low limit of the severe forms. Current PASI and CRP level were not significantly different in the type 1 and type 2 psoriatic cases. The patients' characteristics are summarized and shown in Table 1 .
The mean level of 25(OH)D in psoriatic patients was 12.07 ng/ml (30.18 nmol/l), found at the low limit of insufficiency; related 95% CI range was 10.55 -13.60 ng/ml (26.38-33.99 nmol/l). Summary of data on vitamin D status in studied group with moderate and severe psoriasis is presented in Table 2 .
The assessed levels of 25(OH)D had a seasonal variation: the patients evaluated in the winter and spring had lower levels of 25(OH)D (9.52 and 10.16 ng/ml) than patients admitted in summer and autumn (15.34 and 13.69 ng/ml, respectively), Figure 1 . These seasonal variations can be due to the increased vitamin D synthesis in the skin during summer.
There is no difference in serum 25(OH)D in male and female psoriatic patients.
25(OH)D levels were moderately associated with PASI (r=-0.51, inverse correlation, p=0.002), but were not significantly correlated to BMI (r=-0.09), waist circumference (r=-0.12) and CRP (r=0.27).
44 patients had deficiency of 25(OH)D associated with PASI of 37.73±10.63. 45 patients had insufficiency with PASI of 28.82±11.62. In only 3 patients 25(OH)D was assessed in the range of sufficiency and PASI was 18.67±5.86. The severity of psoriasis, reflected by PASI, was highest in patients with 25(OH)D deficiency and the difference of PASI between patients with deficient and insufficient levels of 25(OH)D was statistically significant (p=0.0002), Figure 2 . However, the difference between the severity of disease in subjects with insufficiency and sufficiency of 25(OH)D was not statistically significant but we need to take into account the very small group of patients with psoriasis with normal 25(OH)D.
We did not find significant differences in 25(OH)D levels between patients with early and late type of psoriasis, as well as when obese are compared to normal and overweight patients. 
DISCUSSION
An increasing number of disorders such as obesity, diabetes, arterial hypertension, rheumatoid arthiritis, with a pathogenic link of chronic inflammation are found to be associated with vitamin D insufficiency and deficiency. It was accepted that the effect of vitamin D on immune regulation is due to its interactions with immune cells such as macrophages and lymphocytes. As a result, the production of IL-17, IL-23 and TNF-α is inhibited and the expression of IL-4 and IL-10 is raised. The immune regulatory role of vitamin D affects both the innate and the adaptive immune system contributing to the immune tolerance of self-structures. Thus, the deficiency of vitamin D may potentiate immune-mediated inflammation (11, 12) . Several studies revealed the negative correlation between the grade of rheumatoid arthritis, spondilarthritis and psoriatic arthritis and the serum levels of inflammatory cytokines (IL-1α, IL-1β, TNF-α, TNF-β, IL-17, IL-23), as well as the serum concentrations of vitamin D (13) (14) (15) . Vitamin D deficiency or insufficiency may play a role in the pathogenesis of psoriasis by immune reactions, inducing disturbed differentiation and increased proliferation rate of keratocytes, as well as stimulating angiogenesis (14, 16) .
Previous clinical analyses have been demonstrating controversies in the relationship between vitamin D deficiency and psoriasis. Population-based study from the United States compared 148 self-reporting cases with mild psoriasis to more than 5800 individuals and failed to establish difference in serum 25(OH)D and prevalence of vitamin D deficiency (17) . Orgaz-Molina and co-workers, however, observed lower serum levels of vitamin D in patients with psoriasis when compared with controls; negative association between low 25(OH)D levels and both CRP and BMI were found by multiple regression analysis (18) . In a study by Gisondi, the participants with psoriasis presented a 2.5 times greater risk of having 25-hydroxyvitamin D deficiency than those without the disease (19) . Ricceri et al. found a prevalence of 68% of vitamin D deficiency and 97% of insufficiency in the patients with psoriasis studied, while the percentages found in the control group were 10% of deficiency and approximately 53% of insufficiency of 25(OH)D (20) .
Accepting the limitation of the absence of control group, our analysis also confirms, that patients with psoriasis are a risk group for vitamin D deficiency and insufficiency. We found 47.83% prevalence of 25(OH)D deficiency. The observed insufficient rate of 96.74% is significantly higher, compared to published data from the Bulgarian population on a corresponding prevalence of 75.8%. The vitamin D status is worse in our patients with moderate to severe psoriasis (mean vitamin D level of 30.18nmol/L) than in the general Bulgarian population (38.75 nmol/L) (21) . Our study demonstrated, that the degree of 25(OH)D deficiency correlates with severity of psoriasis, assessed by PASI.
The effect of vitamin D on immune regulation could suggest the need of supplementation in cases of deficiency and insufficiency. Holick et al, investigating 85 patients with psoriasis established an improvement of PASI, from 18.4±1.0 to 9.7±0.8, after a 6-month treatment with calcitriol (22) . Vitamin D supplementation in deficient patients (9 cases with psoriasis and with vitiligo) is efficient in the decrease of PASI and achieved re-pigmentation of the vitiligo areas (4) . A trial on the therapeutic role of vitamin D supplementation in our psoriatic patients is needed. The influence of markers related to the immune regulatory function of calcitriol (as interleukins and skin antimicrobial peptides) on the severity of psoriasis should be a matter of interest for further studies. 
CONCLUSION

